ClinicalTrials.gg
CompletedNCT06070610Updated Dec 2, 2025Results posted

A Study in Healthy Men to Test Whether BI 1015550 Influences the Amount of Nintedanib and Pirfenidone in the Blood

A Phase 1 interventional study of BI 1015550 and Nintedanib in Healthy, sponsored by Boehringer Ingelheim. Completed at 1 site in Germany. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-02.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
14
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
Male
01

Study summary

The main objective of this trial is to investigate the induction effect of multiple oral doses of BI 1015550 on the pharmacokinetics of nintedanib or pirfenidone.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy male subjects according to the assessment of the investigator, as based on a complete medical history including a physical examination, vital signs (blood pressure (BP), pulse rate (PR)), 12-lead (ECG), and clinical laboratory tests
  2. Age of 18 to 55 years (inclusive)
  3. (BMI) of 18.5 to 29.9 kg/m2 (inclusive)
  4. Signed and dated written in accordance with International Council for Harmonisation-Good Clinical Practice (ICH-GCP) and local legislation prior to admission to the trial

Exclusion criteria

Exclusion Criteria:

  1. Any finding in the medical examination (including BP, PR or ) deviating from normal and assessed as by the investigator
  2. Repeated measurement of systolic blood pressure outside the range of 90 to 140 millimetre of mercury (mmHg), diastolic blood pressure outside the range of 50 to 90 mmHg, or pulse rate outside the range of 45 to 90 beats per minute (bpm)
  3. Any laboratory value outside the reference range that the investigator considers to be of clinical relevance
  4. Any evidence of a concomitant disease assessed as clinically relevant by the investigator
  5. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders (including severe renal or hepatic impairment)
  6. Cholecystectomy or other surgery of the gastrointestinal tract that could interfere with the pharmacokinetics of the trial medication (except appendectomy or simple hernia repair)
  7. Diseases of the central nervous system (including but not limited to any kind of seizures or stroke), and other relevant neurological or psychiatric disorders
  8. History of relevant orthostatic hypotension, fainting spells, or blackouts Further exclusion criteria apply
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
14 participants (actual)

Study arms

  • Experimental
    Reference treatment/Test treatment

    In the reference (R) treatment (period 1, two days of treatment), a single dose of 267 mg pirfenidone was administered on Day 1 and a single dose of 100 mg nintedanib on Day 2. In the test (T) treatment (period 2, ten days of treatment), 18 mg nerandomilast were administered twice daily for 10 days (Day -6 to Day 4). A single dose of 267 mg pirfenidone was administered on Day 1 and a single dose of 100 mg nintedanib was administered on Day 2. A washout period of at least 72 hours separated the last drug administration in the reference period from the first drug administration in the test period.

    Drug: BI 1015550 · Drug: Nintedanib · Drug: Pirfenidone

Interventions

  • BI 1015550

    Also known as: Nerandomilast, JASCAYD®

  • Soft capsules

    Also known as: Ofev®

  • Film-coated tablets

    Also known as: Esbriet®

06

What researchers measure

Primary outcomes

  1. Area Under the Concentration-time Curve of Pirfenidone in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)

    Area under the concentration-time curve of pirfenidone in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz). Geometric least squares mean (adjusted geometric mean) and the standard error (actually adjusted geometric standard error) were calculated using an analysis of variance (ANOVA) model on the logarithmic scale. The pharmacokinetic (PK) endpoints were log-transformed (natural logarithm) prior to fitting the ANOVA model.

    Time frame: At 0, 0:30, 1, 1:30, 2, 3, 4, 6, 8, 10, 12, 24 hours from pirfenidone administration (Period 1) and at 0, 0.30, 1, 1:30, 2, 3, 4, 6, 8, 10, 12, 24 hours from nerandomilast and pirfenidone administration (Period 2)

  2. Area Under the Concentration-time Curve of Pirfenidone in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)

    Area under the concentration-time curve of pirfenidone in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞). Geometric least squares mean (adjusted geometric mean) and the standard error (actually adjusted geometric standard error) were calculated using an analysis of variance (ANOVA) model on the logarithmic scale. The pharmacokinetic (PK) endpoints were log-transformed (natural logarithm) prior to fitting the ANOVA model.

    Time frame: At 0, 0:30, 1, 1:30, 2, 3, 4, 6, 8, 10, 12, 24 hours from pirfenidone administration (Period 1) and at 0, 0.30, 1, 1:30, 2, 3, 4, 6, 8, 10, 12, 24 hours from nerandomilast and pirfenidone administration (Period 2)

  3. Maximum Measured Concentration of Pirfenidone in Plasma (Cmax)

    Maximum measured concentration of pirfenidone in plasma (Cmax). Geometric least squares mean (adjusted geometric mean) and the standard error (actually adjusted geometric standard error) were calculated using an analysis of variance (ANOVA) model on the logarithmic scale. The pharmacokinetic (PK) endpoints were log-transformed (natural logarithm) prior to fitting the ANOVA model.

    Time frame: At 0, 0:30, 1, 1:30, 2, 3, 4, 6, 8, 10, 12, 24 hours from pirfenidone administration (Period 1) and at 0, 0.30, 1, 1:30, 2, 3, 4, 6, 8, 10, 12, 24 hours from nerandomilast and pirfenidone administration (Period 2)

  4. Area Under the Concentration-time Curve of Nintedanib in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)

    Area under the concentration-time curve of nintedanib in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz). Geometric least squares mean (adjusted geometric mean) and the standard error (actually adjusted geometric standard error) were calculated using an analysis of variance (ANOVA) model on the logarithmic scale. The pharmacokinetic (PK) endpoints were log-transformed (natural logarithm) prior to fitting the ANOVA model.

    Time frame: At 24, 24:30, 25, 25:30, 26, 27, 28, 30, 32, 34, 36, 48, 60,72, 96 hours from pirfenidone administration (Period 1) and at 24, 24:30, 25, 25:30, 26, 27, 28, 30, 32, 34, 36, 48, 60,72, 96 hours from nerandomilast and pirfenidone administration (Period 2)

  5. Area Under the Concentration-time Curve of Nintedanib in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)

    Area under the concentration-time curve of nintedanib in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞). Geometric least squares mean (adjusted geometric mean) and the standard error (actually adjusted geometric standard error) were calculated using an analysis of variance (ANOVA) model on the logarithmic scale. The pharmacokinetic (PK) endpoints were log-transformed (natural logarithm) prior to fitting the ANOVA model.

    Time frame: At 24, 24:30, 25, 25:30, 26, 27, 28, 30, 32, 34, 36, 48, 60,72, 96 hours from pirfenidone administration (Period 1) and at 24, 24:30, 25, 25:30, 26, 27, 28, 30, 32, 34, 36, 48, 60,72, 96 hours from nerandomilast and pirfenidone administration (Period 2)

  6. Maximum Measured Concentration of Nintedanib in Plasma (Cmax)

    Maximum measured concentration of nintedanib in plasma (Cmax). Geometric least squares mean (adjusted geometric mean) and the standard error (actually adjusted geometric standard error) were calculated using an analysis of variance (ANOVA) model on the logarithmic scale. The pharmacokinetic (PK) endpoints were log-transformed (natural logarithm) prior to fitting the ANOVA model.

    Time frame: At 24, 24:30, 25, 25:30, 26, 27, 28, 30, 32, 34, 36, 48, 60,72, 96 hours from pirfenidone administration (Period 1) and at 24, 24:30, 25, 25:30, 26, 27, 28, 30, 32, 34, 36, 48, 60,72, 96 hours from nerandomilast and pirfenidone administration (Period 2)

07

Results

Posted Dec 2, 2025

Participant flow

This is an open-label, two-period, fixed-sequence crossover trial to investigate the effect of multiple oral doses of 18 mg nerandomilast on the pharmacokinetics of single oral doses of 100 mg nintedanib or 267 mg pirfenidone.

Period 1 (Reference treatment period)
Participant flow — Period 1 (Reference treatment period)
MilestoneReference treatment/Test treatment
Started14
Completed14
Not completed0
Washout period
Participant flow — Washout period
MilestoneReference treatment/Test treatment
Started14
Completed13
Not completed1
Withdrew: Adverse event1
Period 2 (Test treatment period)
Participant flow — Period 2 (Test treatment period)
MilestoneReference treatment/Test treatment
Started13
Completed12
Not completed1
Withdrew: Adverse event1

Outcome measures

PrimaryArea Under the Concentration-time Curve of Pirfenidone in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)

Area under the concentration-time curve of pirfenidone in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz). Geometric least squares mean (adjusted geometric mean) and the standard error (actually adjusted geometric standard error) were calculated using an analysis of variance (ANOVA) model on the logarithmic scale. The pharmacokinetic (PK) endpoints were log-transformed (natural logarithm) prior to fitting the ANOVA model.

Time frame:
At 0, 0:30, 1, 1:30, 2, 3, 4, 6, 8, 10, 12, 24 hours from pirfenidone administration (Period 1) and at 0, 0.30, 1, 1:30, 2, 3, 4, 6, 8, 10, 12, 24 hours from nerandomilast and pirfenidone administration (Period 2)
Reported as:
Geometric least squares mean · hour * nanogram / milliliter (h*ng/mL)
Area Under the Concentration-time Curve of Pirfenidone in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)
hour * nanogram / milliliter (h*ng/mL)Pirfenidone/Nintedanib alone (Reference)Pirfenidone/Nintedanib in combination with Nerandomilast (Test)
Area Under the Concentration-time Curve of Pirfenidone in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)9597.74 ± NA9786.78 ± NA
Statistical analysis
  • Pirfenidone/Nintedanib alone (Reference) vs Pirfenidone/Nintedanib in combination with Nerandomilast (Test) · Adjusted geometric mean ratio (%): 101.97 · 90% CI 93.59 to 111.10Ratio calculated as test/reference\*100. Intra-individual Geometric coefficient of variation \[%\] = 12.3
PrimaryArea Under the Concentration-time Curve of Pirfenidone in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)

Area under the concentration-time curve of pirfenidone in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞). Geometric least squares mean (adjusted geometric mean) and the standard error (actually adjusted geometric standard error) were calculated using an analysis of variance (ANOVA) model on the logarithmic scale. The pharmacokinetic (PK) endpoints were log-transformed (natural logarithm) prior to fitting the ANOVA model.

Time frame:
At 0, 0:30, 1, 1:30, 2, 3, 4, 6, 8, 10, 12, 24 hours from pirfenidone administration (Period 1) and at 0, 0.30, 1, 1:30, 2, 3, 4, 6, 8, 10, 12, 24 hours from nerandomilast and pirfenidone administration (Period 2)
Reported as:
Geometric least squares mean · hour * nanogram / milliliter (h*ng/mL)
Area Under the Concentration-time Curve of Pirfenidone in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)
hour * nanogram / milliliter (h*ng/mL)Pirfenidone/Nintedanib alone (Reference)Pirfenidone/Nintedanib in combination with Nerandomilast (Test)
Area Under the Concentration-time Curve of Pirfenidone in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)10146.47 ± NA10279.17 ± NA
Statistical analysis
  • Pirfenidone/Nintedanib alone (Reference) vs Pirfenidone/Nintedanib in combination with Nerandomilast (Test) · Adjusted geometric mean ratio (%): 101.31 · 90% CI 93.60 to 109.65Ratio calculated as test/reference\*100. Intra-individual Geometric coefficient of variation \[%\] = 11.4
PrimaryMaximum Measured Concentration of Pirfenidone in Plasma (Cmax)

Maximum measured concentration of pirfenidone in plasma (Cmax). Geometric least squares mean (adjusted geometric mean) and the standard error (actually adjusted geometric standard error) were calculated using an analysis of variance (ANOVA) model on the logarithmic scale. The pharmacokinetic (PK) endpoints were log-transformed (natural logarithm) prior to fitting the ANOVA model.

Time frame:
At 0, 0:30, 1, 1:30, 2, 3, 4, 6, 8, 10, 12, 24 hours from pirfenidone administration (Period 1) and at 0, 0.30, 1, 1:30, 2, 3, 4, 6, 8, 10, 12, 24 hours from nerandomilast and pirfenidone administration (Period 2)
Reported as:
Geometric least squares mean · nanogram / milliliter (ng/mL)
Maximum Measured Concentration of Pirfenidone in Plasma (Cmax)
nanogram / milliliter (ng/mL)Pirfenidone/Nintedanib alone (Reference)Pirfenidone/Nintedanib in combination with Nerandomilast (Test)
Maximum Measured Concentration of Pirfenidone in Plasma (Cmax)2451.85 ± NA2479.00 ± NA
Statistical analysis
  • Pirfenidone/Nintedanib alone (Reference) vs Pirfenidone/Nintedanib in combination with Nerandomilast (Test) · Adjusted geometric mean ratio (%): 101.11 · 90% CI 87.36 to 117.02Ratio calculated as test/reference\*100. Intra-individual Geometric coefficient of variation \[%\] = 21.4
PrimaryArea Under the Concentration-time Curve of Nintedanib in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)

Area under the concentration-time curve of nintedanib in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz). Geometric least squares mean (adjusted geometric mean) and the standard error (actually adjusted geometric standard error) were calculated using an analysis of variance (ANOVA) model on the logarithmic scale. The pharmacokinetic (PK) endpoints were log-transformed (natural logarithm) prior to fitting the ANOVA model.

Time frame:
At 24, 24:30, 25, 25:30, 26, 27, 28, 30, 32, 34, 36, 48, 60,72, 96 hours from pirfenidone administration (Period 1) and at 24, 24:30, 25, 25:30, 26, 27, 28, 30, 32, 34, 36, 48, 60,72, 96 hours from nerandomilast and pirfenidone administration (Period 2)
Reported as:
Geometric least squares mean · hour * nanogram / milliliter (h*ng/mL)
Area Under the Concentration-time Curve of Nintedanib in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)
hour * nanogram / milliliter (h*ng/mL)Pirfenidone/Nintedanib alone (Reference)Pirfenidone/Nintedanib in combination with Nerandomilast (Test)
Area Under the Concentration-time Curve of Nintedanib in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)137.88 ± NA149.43 ± NA
Statistical analysis
  • Pirfenidone/Nintedanib alone (Reference) vs Pirfenidone/Nintedanib in combination with Nerandomilast (Test) · Adjusted geometric mean ratio (%): 108.37 · 90% CI 102.58 to 114.49Ratio calculated as test/reference\*100. Intra-individual Geometric coefficient of variation \[%\] = 7.5
PrimaryArea Under the Concentration-time Curve of Nintedanib in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)

Area under the concentration-time curve of nintedanib in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞). Geometric least squares mean (adjusted geometric mean) and the standard error (actually adjusted geometric standard error) were calculated using an analysis of variance (ANOVA) model on the logarithmic scale. The pharmacokinetic (PK) endpoints were log-transformed (natural logarithm) prior to fitting the ANOVA model.

Time frame:
At 24, 24:30, 25, 25:30, 26, 27, 28, 30, 32, 34, 36, 48, 60,72, 96 hours from pirfenidone administration (Period 1) and at 24, 24:30, 25, 25:30, 26, 27, 28, 30, 32, 34, 36, 48, 60,72, 96 hours from nerandomilast and pirfenidone administration (Period 2)
Reported as:
Geometric least squares mean · hour * nanogram / milliliter (h*ng/mL)
Area Under the Concentration-time Curve of Nintedanib in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)
hour * nanogram / milliliter (h*ng/mL)Pirfenidone/Nintedanib alone (Reference)Pirfenidone/Nintedanib in combination with Nerandomilast (Test)
Area Under the Concentration-time Curve of Nintedanib in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)145.03 ± NA157.82 ± NA
Statistical analysis
  • Pirfenidone/Nintedanib alone (Reference) vs Pirfenidone/Nintedanib in combination with Nerandomilast (Test) · Adjusted geometric mean ratio (%): 108.82 · 90% CI 102.54 to 115.49Ratio calculated as test/reference\*100. Intra-individual Geometric coefficient of variation \[%\] = 7.7
PrimaryMaximum Measured Concentration of Nintedanib in Plasma (Cmax)

Maximum measured concentration of nintedanib in plasma (Cmax). Geometric least squares mean (adjusted geometric mean) and the standard error (actually adjusted geometric standard error) were calculated using an analysis of variance (ANOVA) model on the logarithmic scale. The pharmacokinetic (PK) endpoints were log-transformed (natural logarithm) prior to fitting the ANOVA model.

Time frame:
At 24, 24:30, 25, 25:30, 26, 27, 28, 30, 32, 34, 36, 48, 60,72, 96 hours from pirfenidone administration (Period 1) and at 24, 24:30, 25, 25:30, 26, 27, 28, 30, 32, 34, 36, 48, 60,72, 96 hours from nerandomilast and pirfenidone administration (Period 2)
Reported as:
Geometric least squares mean · nanogram / milliliter (ng/mL)
Maximum Measured Concentration of Nintedanib in Plasma (Cmax)
nanogram / milliliter (ng/mL)Pirfenidone/Nintedanib alone (Reference)Pirfenidone/Nintedanib in combination with Nerandomilast (Test)
Maximum Measured Concentration of Nintedanib in Plasma (Cmax)16.18 ± NA14.12 ± NA
Statistical analysis
  • Pirfenidone/Nintedanib alone (Reference) vs Pirfenidone/Nintedanib in combination with Nerandomilast (Test) · Adjusted geometric mean ratio (%): 87.24 · 90% CI 75.27 to 101.11Ratio calculated as test/reference\*100. Intra-individual Geometric coefficient of variation \[%\] = 20.5

Adverse events

Collected over - For pirfenidone and for nerandomilast + pirfenidone: From administration of pirfenidone + Residual Effect Period (REP) of 12 hours, up to 1 day - For nintedanib and for nerandomilast + nintedanib: From administration of nintedanib + REP of 3 days, up to 3 days - For nerandomilast: up to 12 days - All cause-mortality: up to 25 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pirfenidone0/14 (0%)0/14 (0%)1/14 (7.1%)
Nintedanib0/14 (0%)0/14 (0%)4/14 (28.6%)
Nerandomilast0/13 (0%)0/13 (0%)3/13 (23.1%)
Nerandomilast+pirfenidone0/13 (0%)0/13 (0%)1/13 (7.7%)
Nerandomilast+nintedanib0/13 (0%)0/13 (0%)7/13 (53.8%)
Most frequent other events
Showing 10 of 12
Most frequent other events
EventPirfenidoneNintedanibNerandomilastNerandomilast+pirfenidoneNerandomilast+nintedanib
DizzinessNervous system disorders0/141/141/130/133/13
HeadacheNervous system disorders0/142/141/130/133/13
DiarrhoeaGastrointestinal disorders0/142/140/130/132/13
NauseaGastrointestinal disorders0/140/141/130/132/13
Abdominal discomfortGastrointestinal disorders0/141/141/130/131/13
Abdominal painGastrointestinal disorders0/141/140/130/131/13
DyspepsiaGastrointestinal disorders0/140/140/131/130/13
FlatulenceGastrointestinal disorders0/140/140/130/131/13
Gastrointestinal painGastrointestinal disorders0/140/140/130/131/13
NasopharyngitisInfections and infestations0/140/140/130/131/13

Baseline characteristics

Treated set (TS): The treated set included all subjects who were treated with at least 1 dose of trial drug.

Age, Continuous
Age, Continuous(Years)Reference Treatment/Test Treatment
Mean36.3 ± 10.9
Sex: Female, Male
Sex: Female, Male(Participants)Reference Treatment/Test Treatment
Female0
Male14
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Reference Treatment/Test Treatment
Hispanic or Latino0
Not Hispanic or Latino14
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Reference Treatment/Test Treatment
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White14
More than one race0
Unknown or Not Reported0
08

Study locations

1 site
  • Humanpharmakologisches Zentrum Biberach
    Biberach, 88397, Germany
09

References and documents

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents. Exceptions might apply, e.g. studies in products where Boehringer Ingelheim is not the license holder; studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; studies conducted in a single center or targeting rare diseases (in case of low number of patients and therefore limitations with anonymization). For more details refer to: https://www.mystudywindow.com/msw/datatransparency

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2023 to primary completion in Dec 2023, 1 month.

Results were first posted in Dec 2025, 1 year 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 2, 2023
First posted
Oct 6, 2023
StartActual
Nov 8, 2023
Primary completionActual
Dec 14, 2023
CompletionActual
Dec 14, 2023
Results first posted
Dec 2, 2025
Last update
Dec 2, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 2, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06070610
Responsible party
Sponsor
First posted
Oct 6, 2023
Start date
Nov 8, 2023
Primary completion
Dec 14, 2023
Completion
Dec 14, 2023
Results posted
Dec 2, 2025
Last update
Dec 2, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Nerandomilast · Nintedanib · Pirfenidone

Start the discussion